Genome editing using zinc finger nucleases (ZFNs) has been successfully applied to disrupt CCR5 or CXCR4 host factors and inhibit viral entry and infection. Gene therapy using ZFNs to modify the PSIP1 gene, which encodes the lens epithelium-derived growth factor (LEDGF) protein, might restrain an early step of the viral replication cycle at the integration level. ZFNs targeting the PSIP1 gene (ZFN LEDGF ) were designed to specifically recognize the sequence after the integrase binding domain (IBD) of the LEDGF/p75 protein. ZFN LEDGF successfully recognized the target region of the PSIP1 gene in TZM-bl cells by heteroduplex formation and DNA sequence analysis. Gene editing induced a frameshift of the coding region and resulted in the abolishment of LEDGF expression at the mRNA and protein levels. Functional assays revealed that infection with the HIV-1 R5 BaL or X4 NL4-3 viral strains was impaired in LEDGF/p75 knockout cells regardless of entry tropism due to a blockade in HIV-1 proviral integration into the host genome. However, residual infection was detected in the LEDGF knockout cells. Indeed, LEDGF knockout restriction was overcome at a high multiplicity of infection, suggesting alternative mechanisms for HIV-1 genome integration rather than through LEDGF/p75. However, the observed residual integration was sensitive to the integrase inhibitor raltegravir. These results demonstrate that the described ZFN LEDGF effectively targets the PSIP1 gene, which is involved in the early steps of the viral replication cycle; thus, ZFN LEDGF may become a potential antiviral agent for restricting HIV-1 integration. Moreover, LEDGF knockout cells represent a potent tool for elucidating the role of HIV integration cofactors in virus replication.
H
uman immunodeficiency virus (HIV) requires the host cellular machinery in order to successfully replicate (1) . The development of genome-editing tools, such as zinc finger endonucleases (ZFNs) (2) , transcription activator-like effector nucleases (TALEN) (3) , and clustered regularly interspaced short palindromic repeats (CRISPR) (4) (5) (6) , has introduced a promising alternative for the modification of essential host factors along the replication cycle of HIV (7, 8) . ZFNs have demonstrated their applicability to reproduce the CCR5⌬32 phenotype in vitro by successfully cleaving the CCR5 gene, generating human CD4 ϩ T cells refractory to HIV-1 infection (9) (10) (11) (12) . Similarly, a ZFN approach successfully cleaved the alternative HIV-1 coreceptor CXCR4 in CD4 ϩ T cells in a humanized mouse model, resulting in impaired HIV-1 infection (13) . Genome editing as anti-HIV therapy is currently under study in at least 2 or 3 clinical trials using ZFNs targeting CCR5. However, similar strategies targeting host cellular factors affecting the later steps of the virus replication cycle have not been evaluated.
A crucial step of the viral replication cycle is exerted by the lens epithelium-derived growth factor (LEDGF), a member of the hepatoma-derived growth factor (HDGF)-related protein (HRP) family. HRPs are characterized by a conserved N-terminal PWWP domain, a 90-to 135-amino-acid module found in a variety of nuclear proteins (14) . Six human HRP family members have been described: HDGF, HRP1, HRP2, HRP3, LEDGF/p75, and LEDGF/p52. Two of them, LEDGF/p75 and HRP2, possess affinity for HIV-1 integrase (IN), given by a second evolutionarily conserved domain within their C termini that mediates the interaction with HIV-1 IN, hence the term IN-binding domain (IBD) (15) . Initially identified as an IN-associated protein (16) , LEDGF/ p75 was revealed to be a lentivirus-specific cellular cofactor required for HIV integration into the host genome (see references 17 to 19 for review). LEDGF/p75 directly interacts with viral HIV-IN, tethering a viral preintegration complex into the active transcription units of the cellular chromatin. The role of LEDGF/p75 in HIV-1 replication was studied using RNA interference (RNAi) targeting LEDGF/p75 and LEDGF knockout (KO) mouse embryonic fibroblasts (MEFs). Although both strategies potently downregulated or completely abolished LEDGF/p75 expression, residual replication was observed. Thus, all studies point to a key but not essential role for LEDGF/p75 in lentiviral replication and suggest that the existence of alternative cellular cofactors, such as HRP2, are responsible for the residual replication observed in the absence of LEDGF/p75 (20, 21) .
Nevertheless, the LEDGF/p75 interaction with HIV IN has been suggested as a valid target for antiviral therapy (22) (23) (24) . In that sense, recently developed allosteric LEDGF/p75-IN interaction inhibitors (LEDGINs and ALLINIS) have been proven to target the LEDGF/p75 binding pocket of HIV IN and to inhibit the catalytic activity of the IN. Moreover, LEDGINs and ALLINIS also exert antiviral activity by promoting IN multimerization. Aberrant IN complexes lead to the formation of defective regular cores during the maturation process, resulting in an impaired infectivity in the new viral particles (25) (26) (27) .
On the other hand, a series of PSIP1 single nucleotide polymorphisms (SNP) were associated with HIV-1 disease progression in cohorts of African and Caucasian HIV-1-positive individuals (28, 29) . In addition, two missense mutations were identified in two samples belonging to a long-term nonprogression (LTNP) cohort (30) . All identified missense mutations are located in the helixturn-helix (HTH) motifs at the C-terminal region of the protein, which is after the IBD. Although none of the mutations restricted HIV replication in vitro (29, 31, 32) , these findings suggest that genetic variation in PSIP1 may influence susceptibility to HIV-1 infection and disease progression.
Here, we describe a novel genome-editing ZFN that specifically disrupts the PSIP1 gene encoding LEDGF/p75 in its C terminus, which is found after all relevant functional domains and near the missense mutations that have been described in patients (ZFN LEDGF ). ZFN LEDGF was able to generate LEDGF/p75 cells expressing a truncated protein that becomes refractory to HIV-1 integration. The LEDGF/p75 knockout cells generated represent a potent tool for further investigation of the function of the LEDGF/ p75 protein, and they may help to elucidate the role of HIV integration cofactors in virus replication. Moreover, ZFN LEDGF may become an antiviral strategy for restricting HIV-1 integration and virus replication in vivo.
MATERIALS AND METHODS

Vectors.
CompoZr knockout zinc finger nucleases targeting the PSIP1 gene (ZFN LEDGF ) were obtained from Sigma-Aldrich Biotechnology (St. Louis, MO, USA). Briefly, ZFN LEDGF were designed to target the sequence AACATGTTCTTGGTTGGTGAAGGAGATTCCGTG (Fig. 1a) , according to the guidelines of Mussolino and Cathomen (33) , to ensure minimal homology of the ZFN DNA-binding domain to any other site in the genome. The FokI and zinc finger domains of each ZFN pair were assembled as previously described (34) . Next, the ZFN LEDGF pairs were cloned into the pLVX-IRES-ZsGreen1 vector (Clontech), by replacing the EcoRI-XbaI fragment, to obtain ZFN LEDGF tagged with the green fluorescent reporter gene (pLVX-ZFNLEDGF-ZsGreen).
Cells. Human K562 cells were obtained from the ATCC (CCL-243) and grown in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. The TZM-bl cell line (NIH AIDS Research and Reference Program) was grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Life Technologies, Madrid, Spain), supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco, Thermo Fisher, Madrid, Spain) and antibiotics (100 U/ml penicillin, 100 g/ml streptomycin [Life Technologies]), and maintained at 37°C in a 5% CO 2 incubator.
ZFN transfection. The TZM-bl cells were transfected with ZFN LEDGFexpressing plasmids, as described previously (35, 36) . Briefly, 1.5 ϫ 10 5 cells were seeded in 24-well plates. After overnight culture, 0.5 g of each ZFN LEDGF plasmid was mixed with Lipofectamine 2000 reagent (Invitrogen) in the serum-free medium Opti-MEM (Invitrogen) and then added to previously washed cells. The medium was replaced by fresh DMEM 4 h after transfection and left in the incubator for 3 days, when ZsGreenpositive cells were sorted using a FACSAria II (BD Biosciences) flow cytometer. Single-cell clones were obtained by limiting dilution seeding of the sorted cells in 96-well plates.
Analysis of PSIP1 disruption by CEL-I assay. The effect of ZFN on the PSIP1 alleles was assessed by performing PCR on the region surrounding the ZFN target site, followed by digestion with the Surveyor (CEL-1) nuclease assay (Transgenomic, Omaha, NE, USA), which cleaves DNA heteroduplex formations at the mismatch sites. The generated fragments were resolved by 10% polyacrylamide electrophoresis, as previously described (10, 12) .
Sequence analysis of targeted PSIP1 gene in TZM-bl cells. Genomic DNA from the sorted cell clones was extracted using the QIAamp DNA blood minikit (Qiagen, Barcelona, Spain). Extracted DNA was used to amplify the LEDGF gene using the Expand high-fidelity PCR system (Roche, Barcelona, Spain) and the forward primer 5=-TTCAAGTCATGT GGATTCTTTGA-3= and reverse primer 5=-TCTAGCTTTTTGTTTGGC CC-3=. The PCR products were cloned into the pGEM-T Easy vector system (Promega, Madrid, Spain), according to the manufacturer's instructions. Plasmid sequencing was carried out by the Macrogen Genomic Division, Seoul, South Korea, using ABI Prism BigDye Terminator cycle sequencing technology (Applied Biosystems), with the following internal primers of the PSIP1 genomic sequence: forward, 5=-TTGGAAACGATC TTTAGAAACAGA-3=, and reverse, 5=-CAGTGAAACTATGTATGAAA GCCATT-3=. When bigger deletions were observed, the sequences were obtained directly from the mRNA sequence (see above). The sequences were analyzed with the Sequencher 4.5 software (Gene Codes Corporation, Ann Arbor, MI, USA). In addition, a bioinformatics algorithm (Sigma) was used to evaluate the putative off-target effects for ZFN LEDGF throughout the human genome.
In silico prediction of the mRNA and protein sequences of the edited cell clones was performed using the ExPASy SIB bioinformatics resource portal (37) .
Quantitative RT-PCR and mRNA expression assessment. Relative mRNA quantification of PSIP1 expression was assessed by reverse transcription-quantitative PCR (RT-qPCR), as previously described (38, 39) . Briefly, RNA was extracted using the Qiagen RNeasy extraction minikit (Qiagen), according to the manufacturer's instructions, including the DNase I treatment step. Reverse transcription was performed using the High-Capacity cDNA reverse transcription kit (Life Technologies, Madrid, Spain). To assess the presence of the predicted PSIP1 mRNA truncated forms, the mRNA sequence was divided into two fragments of similar size, which were PCR amplified with primers for the 5=-containing fragment: forward primer 5=-GGCAAACCAAATAAAAGAAAAGG-3= and reverse primer 5=-CTTGCTTGCGTTTTCGATCT-3=; the primers for the 3=-containing fragment were forward primer 5=-AAAAGGTGGG AGGAACTTTCA-3= and reverse primer 5=-GCAGTCTATTTCAAATGA AAACCAT-3= Relative gene expression of the PSIP1 wild-type form was also measured by two-step quantitative RT-PCR and normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene expression using the delta-delta threshold cycle (C T ) method. The primers and DNA probes were purchased from Life Technologies.
Western blot assay. The treated cells were rinsed in ice-cold phosphate-buffered saline (PBS), nuclear proteins were enriched using the CelLytic NuCLEAR extraction kit (Sigma), and extracts were prepared in lysis buffer (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 10 mM Na ␤-glycerophosphate, 50 mM NaF, 5 mM Na pyrophosphate, 270 mM sucrose, and 1% Triton X-100) supplemented with protease inhibitor cocktail (Roche) and 1 mM phenylmethylsulfonyl fluoride. The samples were run using a NuPAGE 4 to 12% Bis-Tris gel (Novex, Life Technologies) and blotted onto nitrocellulose membranes. The blocked membranes were incubated overnight with monoclonal antibodies (MAbs) against the human C-terminal LEDGF protein (C57G11; Cell Signaling Technologies), human N-terminal LEDGF protein (clone 26, 611714; BD Transduction Laboratories), and ␤-actin (Sigma-Aldrich) at 4°C. After washing, the membranes were incubated with a secondary horseradish peroxidase-conjugated antibody for 1 h at room temperature and then revealed with SuperSignal West Pico chemiluminescent substrate (Pierce Chemical, Rockford, IL).
Virus production and infections. Vesicular stomatitis virus (VSV)-pseudotyped NL4-3 green fluorescent protein (GFP)-expressing virus (40) was produced as described previously (39) . The HIV-1 viral strains BaL (R5 tropic) and NL4-3 (X4 tropic) were obtained from the MRC Centre for AIDS Reagents (London, United Kingdom). The BaL and NL4-3 strains were grown in peripheral blood mononuclear cells (d) Gene editing by ZFN LEDGF induces heteroduplex formation determined by the surveyor mutation assay (CEL-I). After genomic DNA extraction, heteroduplex formation due to the generation of insertions or deletions was assessed by the surveyor mutation assay. DNA fragments were resolved in a 10% Tris-borate-EDTA (TBE)-PAGE gel. The lower migrating products (arrows) are a direct measure of ZFN-mediated gene disruption. ϩ/Ϫ, clone 1 (heterozygous); Ϫ/Ϫ, clone 2 (homozygous).
␤-galactosidase assays, the cells were lysed 72 h after infection and kept frozen until ␤-galactosidase determination.
To assess the effect of ZFN LEDGF on viral integration, the cells were infected with NL4-3, and after 8 h of infection, the cells were lysed and DNA was harvested to measure the amount of viral DNA. To determine viral integration, the cells were infected, and 8 h after infection, fresh growth medium supplemented with 10 g/ml of the neutralizing antigp120 MAb IgG b12 (Polymun Scientific) was added and left in the incubator for 24 h, when DNA was harvested and stored at Ϫ20°C until the integration of viral DNA was determined.
␤-Galactosidase detection assay. ␤-Galactosidase activity in 30-l cell extracts was quantified by a colorimetric assay, as described elsewhere (39, 41) . The absorbances (405 to 620 nm) of the noninfected samples were subtracted from those of the rest of the samples, and the values were expressed as a percentage of ␤-galactosidase activity relative to the nondrug-treated control.
Viral and integrated DNA determination. Viral DNA was extracted using a QIAamp DNA extraction kit (QIAamp DNA blood minikit; Qiagen). Total viral DNA was quantified by amplifying a Gag fragment, as described elsewhere (forward primer, 5=-CAAGCAGCCATGCAAATGT T-3=; reverse primer, 5=-TGCACTGGATGCAATCTATCC-3=; probe, 5=-FAM-AAAGAGACCATCAATGAGGAAGCTGCAGA-TAMRA-3= [FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine]) (39, 41) . Integration was detected by Alu-long terminal repeat (LTR) preamplification (Alu forward primers 5=-GCCTCCCAAAGTGCTGGGATTA CAG-3= and LTR reverse primer 5=-AGGGTTCCTTTGGTCCTTGT-3=, followed by Gag quantitative PCR (qPCR).
Statistical analyses. The experimental data are presented as means Ϯ standard deviation (SD). A paired Student's t test was used for comparing two groups, using the GraphPad Prism software (GraphPad Software, San Diego, CA, USA). A P value of 0.05 was considered statistically significant.
RESULTS
Design and efficiency of ZFN LEDGF . ZFNs targeting PSIP1 were designed to specifically disrupt the C-terminal region where mutations in HIV patients have been identified, which is found after the sequence coding for the IBD of LEDGF/p75 (Fig. 1a) (30, 32) . The endonuclease activity of ZFN LEDGF was determined in vitro in K562 cells and by assessing heteroduplex formation in the surrounding region of the targeted DNA sequence within the PSIP1 gene. Endonuclease activity in human K562 cells was estimated to be 6.6% when transfecting plasmids encoding the ZFN, increasing to 12% when using ZFN mRNA. The applicability of ZFNs is hampered by the potential risk of off-site cutting events leading to undesired side effects (42) . Since off-target events have been reported for the previously described ZFNs targeting the CCR5 gene (43, 44) , the possibility of off-site cutting events for ZFN LEDGF was assessed in silico. The in silico analysis predicted up to 19 potential off-target sites for ZFN LEDGF , all with Ն4 mismatches compared to the target sequence and corresponding to 9 coding regions distributed in 7 different chromosomes of the human genome (see Table S1 in the supplemental material).
To improve ZFN efficiency and speed up the selection of single-cell clones edited by ZFN LEDGF , the sequence encoding ZFN LEDGF was cloned in plasmids carrying a ZsGreen fluorescence reporter gene, whose expression was transient. After transfection, 15% of the cells were ZsGreen positive, a population that was enriched to 95% ZsGreen-positive cells by cell sorting. Monoclonal cell populations of ZFN LEDGF -treated cells were obtained by limiting dilution, resulting in 38 single clonal cell lines, of which 6 were discarded due to slow growth kinetics. Thus, further functional characterization was performed in 32 clonal cell lines.
The ZFN LEDGF -treated clonal cell lines were screened for their capacity to restrict single-round HIV-1 infection by measuring the fluorescence induced by a VSV-pseudotyped NL4-3 GFP-expressing virus. Although different degrees of HIV infection were identified, 25 of 32 cell lines blocked HIV replication Ͼ50% compared to the wild-type control cells, suggesting that the PSIP1 gene has been effectively targeted and genomically edited (Table 1) . In only 7 cell lines were residual or no effects on HIV replication observed, representing an efficiency of 70% for the overall experimental procedure. Next, three of the cell lines were chosen for further validation, taking into account their different degrees of HIV infection impairment (Fig. 1c) . The deletions/insertions induced by ZFN LEDGF were additionally confirmed using the heteroduplex formation assay in selected cell lines (Fig. 1d) . 
Molecular characterization of ZFN LEDGF -edited cell lines.
To characterize the genomic defects introduced by ZFN LEDGF , the PSIP1 genomic sequence surrounding the target site of the selected clonal cell lines was amplified, cloned, and sequenced. At least 16 different PSIP1 sequences were obtained from each selected cell line, and the sequences were aligned, thus confirming that ZFN LEDGF successfully recognized and cleaved the target sequence. Two cell lines harbored large modifications in both alleles (LEDGF Ϫ/Ϫ KO, cell lines 2 and 3), whereas another cell line, together with a large modification, presented a 3-bp deletion that led to a single amino acid deletion at the protein level, thus resembling a heterozygotic phenotype (LEDGF ϩ/Ϫ , cell line 1) (Fig. 2a) . Sequencing analysis and alignment confirmed that ZFN LEDGF introduced genomic defects located in exon 13, in most cases occurring after the IBD. The genomic defects detected were three deletions of 3 bp, 41 bp, and 17 bp, one insertion of 155 bp, and two very large deletions that could not be well characterized at the genomic level but were characterized at the mRNA level (Fig. 2a and data not shown). In silico prediction of the putative mRNA and protein sequences of the LEDGF Ϫ/Ϫ KO cell lines suggested the presence of a truncated protein with a conserved functional PWWP domain (both alleles of cell lines 1, 2, and 3) and IBD (cell line 1, allele A and cell line 2, allele B) but lacking the C-terminal part ( Fig. 2b and c) .
The effect of ZFN LEDGF on gene expression was assessed at both the mRNA and LEDGF/p75 protein levels using RT-qPCR and Western blot assay, respectively. In silico prediction of a truncated mRNA was confirmed by testing mRNA expression of the 5= and 3= fragments of the PSIP1 gene. Expression of the PSIP1 5= mRNA fragment (from PSIP1 mRNA positions ϩ204 to ϩ951) was detected in cDNA samples of all selected cell lines (Fig. 2d) . Conversely, expression of the PSIP1 3= mRNA (from PSIP1 mRNA position ϩ864 to position *66 after the stop codon), which included the ZFN LEDGF cutting site, was not detected in the LEDGF Ϫ/Ϫ KO cell lines with larger deletions (cell lines 2 and 3), but it was present in cell line 1, resembling a heterozygote compared to the wild-type or mock-transfected controls (Fig. 2d) . Cell line 1 also presented a smaller mRNA fragment, indicative of a large deletion, the boundaries of which cannot be characterized at the genomic level. However, we identified an mRNA form lacking exons 12, 13, and 14 by cloning and sequencing the cDNA products, indicating that the induced deletion expanded over at least the 700-bp genomic region that includes all 3 exons (Fig. 2c) .
To confirm mRNA truncation, a quantitative analysis of gene expression corresponding to the C-terminal end of the PSIP1 gene was performed, confirming a significant decrease in C-terminal mRNA expression in ZFN LEDGF -treated cells compared to the wild-type and mock-transfected cells (60% reduction in heterozygotic cells, residual expression in homozygotes; P Ͻ 0.01; Fig. 2d) . Similarly, when using an antibody specifically recognizing the LEDGF/p75 C terminus, no protein expression was observed in cell lines 2 and 3, but it was partly detected in cell line 1, further confirming that ZFN LEDGF induces the formation of a truncated sequence that leads to a potent abrogation of complete LEDGF/ p75 expression at the mRNA and protein levels (Fig. 2d, e, and  upper panel of f) .
Deletions in the IBD C terminus of LEDGF have been reported to affect protein stability and reduce the solubility of the protein (15) . Thus, to determine whether the predicted truncated proteins were effectively expressed, a monoclonal antibody recognizing the N-terminal region of LEDGF was used. Expression of the fulllength p75 and p52 isoforms was detected in the control cell lines (wild type and mock transfected; Fig. 2f, lower panel, first two  lanes) , as well as in edited cell line 1 (Fig. 2f, lane 4) , whereas only the p52 isoform was detected in cell lines 2 and 3 (Fig. 2f, lanes 3  and 5) , confirming the results obtained with the C-terminal antibody. However, a band of intermediate molecular weight (MW) appeared in cell lines 1 and 3 (Fig. 2f, red arrows) , which was in accordance with our in silico predictions (predicted molecular mass: LEDGF/p75, 60.1 kDa; LEDGF/p52, 37 kDa; and truncated proteins, 47 to 48 kDa; based on ExPASy prediction tools [37] ) and therefore suggested the expression of LEDGF-truncated proteins. No clear protein expression was detected in cell line 2, suggesting that the genomic modifications induced in this cell line compromised protein stability, solubility, and/or folding, as previously reported for other truncated LEDGF constructs (15) .
HIV-1 infection. Functional assays to establish the effect of ZFN LEDGF were performed with the LEDGF ϩ/Ϫ (cell line 1) cells and one homozygote LEDGF Ϫ/Ϫ KO cell (cell line 2). No differences in the growth kinetics of the cell lines compared to that of the control parental cells were observed (data not shown). The LEDGF ϩ/Ϫ and LEDGF Ϫ/Ϫ KO cells were challenged with either HIV-1 X4-tropic NL4-3 or R5-tropic BaL strains, and infection was monitored by ␤-galactosidase (␤-Gal) production (Fig. 3) . The LEDGF ϩ/Ϫ cell line slightly inhibited HIV-1 infection compared to the wild-type and mock-transfected controls (24% and 45% inhibition for the HIV-1 X4 NL4-3 and R5 BaL strains, respectively) (Fig. 3a and b) . Conversely, HIV-1 infection in the LEDGF Ϫ/Ϫ KO cells was strongly inhibited compared to that in the wild type and mock-transfected control, regardless of the viral strain used (up to 70%, P Ͻ 0.01) (Fig. 3a and b) . Nevertheless, and in line with previous reports, infection was not completely abolished in the KO cell line, and residual infection persisted, accounting for roughly 30% of the infections for both the R5 BaL and X4 NL4-3 viral strains ( Fig. 3a and b) . To evaluate the effect of antiviral compounds in the ZFN LEDGF cell lines, the antiviral activities of the X4 entry inhibitor AMB3100, the reverse transcriptase inhibitor AZT, and the integrase inhibitor raltegravir were determined ( Fig. 3c and d) . No significant differences were observed in the efficacies of the different compounds for any of the drugs tested. Interestingly, raltegravir was able to inhibit the residual replication observed in the LEDGF Ϫ/Ϫ KO cells, consiscorresponding to the 5= and 3= regions. Shown is an agarose gel with which the presence or absence of 5= and 3= fragments of PSIP1 mRNA was identified. In the case of cell line 1, the full-length and a truncated form of the 3= mRNA fragment were identified. Ctrl, control. tent with previous reports (20, 21) and confirming the different mechanism of action for the two strategies.
To further characterize the functionality of ZFN LEDGF , viral and integrated viral DNA were determined in the LEDGF Ϫ/Ϫ KO cell line. No differences were observed in the HIV-1 DNA between the mock-transfected cells and LEDGF Ϫ/Ϫ KO cells when challenged with HIV-1 X4 NL4-3 (Fig. 4a) . Conversely, integrated viral DNA was inhibited up to 87% in the LEDGF Ϫ/Ϫ KO cells compared to the viral integration in the mock-transfected control (P Ͻ 0.001, Fig. 4b ). Residual viral integration was also observed in the LEDGF Ϫ/Ϫ KO cells (approximately 12% of integration, P Ͻ 0.001) (Fig. 4b) , which was fully inhibited by the IN inhibitor raltegravir (Fig. 4b) .
Altogether, these results suggest that a complete LEDGF/p75
protein, including the C-terminal domain, is necessary to successfully tether the HIV preintegration complex to the active transcriptional units. Consistent with previous reports (19) (20) (21) , LEDGF Ϫ/Ϫ KO cells were able to support inefficient but detectable viral integration and produce new viral particles, confirming the presence of alternative pathways for HIV-1 replication in the absence of LEDGF/p75.
DISCUSSION
Genome editing is an emerging strategy for studying virus-host interactions and to combat and cure HIV-1 infection (7, 8) . An ideal therapy for HIV or other chronic viral infections that course with latent reservoirs is believed to involve the generation of a source of long-lived, self-renewing, and multilineage hematopoi- etic stem cells that repopulate the host with genetically modified cells that are refractory to infection (45, 46) . Since the unique and exceptional case of an HIV-1 sterilizing cure of a patient due to bone marrow transplantation with a matched donor homozygote for the CCR5⌬32 mutation (47, 48) , alternative strategies have aimed to reproduce the CCR5⌬32 phenotype using genome-editing tools. Indeed, ZFNs targeting the HIV coreceptor gene have been successfully developed to generate human CD4 ϩ T cells and human embryonic cell precursors and induce pluripotent stem cells that were refractory to HIV-1 infection in different mouse models (9) (10) (11) (12) (13) .
Here, we evaluated the feasibility and efficacy of generating a cell line with knockout of LEDGF/p75, a key factor for the integration of viral DNA into the host genome, using ZFNs targeting the C-terminal region of the LEDGF/p75 protein, outside the best-described functional PWWP and IBD. LEDGF/p75 has already been validated as a candidate for gene therapy in a model in which engraftment of lentivirus-transduced CD4 ϩ T cells overexpressing a truncated form of LEDGF (LEDGF 325-530 ) induced a 3-log reduction in plasma viral load of HIV-1-infected mice (23) . Overexpression of the deficient mutant LEDGF 325-530 in primary CD4 ϩ T cells impeded but did not completely block viral replication, due to minimal wild-type LEDGF/p75 expression. Thus, the use of ZFN LEDGF might be advantageous in gene therapy settings, as it confers a permanent disruption of the target gene, avoiding the presence of residual levels of the wild-type LEDGF/p75 form that might be hijacked by the HIV IN to successfully replicate.
Here, the use of ZFN LEDGF generated TZM-bl cell lines carrying a truncated form of PSIP1 at the genomic region encoding the protein C-terminal region that preserves the N-terminal functional domains. Although the C-terminal region of LEDGF/p75 is poorly functionally characterized, several genetic variants in HIVinfected patients have been identified outside the known functional domains, variants that might be related to different susceptibilities to HIV infection and disease outcomes (28) (29) (30) . Although the identified LEDGF/p75 variants support efficient HIV-1 infection ex vivo, the C-terminal amino acid positions involved are well conserved throughout the evolution, suggesting an important role for protein functionality (31, 32) . The induction of large deletions in the sequence of the PSIP1 gene coding for the C-terminal region of the LEDGF/p75 protein resulted in an LEDGF Ϫ/Ϫ KO phenotype and provided a genetic barrier to HIV-1 infection in vitro.
A previous work reported a decrease in protein stability, expression levels, and solubility of recombinant LEDGF/p75 mutants lacking an IBD and/or C terminus (15) . In accordance, a stable expression of truncated proteins was detected in only 2 of the 5 edited alleles harboring large modifications, pointing to a need for the LEDGF/p75 C-terminal domain for warranting protein stability and/or correct folding. Our data reinforce the relevance of the C-terminal-end region for LEDGF function and HIV infection outcome, even if the N-terminal functional domains and the IBD of the LEDGF/p75 remain intact. The inhibition of the HIV-1 infection in our ZFN LEDGF clones might seem less apparent than those of previously described LEDGF/p75 knockout models using mouse embryonic fibroblasts (MEFs) (19) and/or LEDGF KO in human somatic NALM-6 cells (pre-B acute lymphoblastic leukemia cell line) (20) . However, LEDGF/p75 KO cells were generated by genetic modifications at exons 2 and 3 of the PSIP1 gene in the MEF model (19) and in human somatic NALM-6 cells by homologous recombination of exons 11 to 14 containing the IBD (20) . Contrary to previous models, our ZFN LEDGF was not designed against the functional domains of the LEDGF protein, strengthening the relevance of the C-terminal end of the protein.
The modulation of LEDGF/p75 expression by different approaches involving RNA interference (49), short-hairpin RNA knockdown (50) , and knockout models (19, 20) has provided strong evidence of how LEDGF/p75 interacts with the HIV IN and tethers HIV proviral DNA to the host chromatin; however, in accordance with our results, it also indicates that residual HIV infection occurred even in the absence of LEDGF/p75. Indeed, HRP2, which has similar structural features as LEDGF/p75, has been postulated as an alternative factor triggering HIV integration (21, 51) . Nevertheless, double PSIP1/HRP2 KO mouse cells are still able to support HIV-1 integration (21); thus, alternative pathways that might allow virus to overcome LEDGF/p75 deficiency cannot be excluded. In that sense, and given that the TZM-bl cell line is a widely accepted model of HIV infection research, our recently developed TZM-bl LEDGF/p75
Ϫ/Ϫ KO model is a helpful tool for elucidating the host factors involved in HIV integration.
In summary, we describe the generation of LEDGF/p75 knockout cells using a ZFN that successfully recognizes and disrupts the sequence of the PSIP1 gene coding for the C-terminal end of the LEDGF/p75 protein. The truncation of the C-terminal end of the LEDGF/p75 protein results in reduced stability, which leads to the generation of KO cells with an impaired HIV-1 replication independent of genetic modification concerning the N-terminal Our results confirm previous data indicating that pathways other than LEDGF/p75 might allow for HIV integration. Finally, ZFN LEDGF provides a new cellular model for studying the host factors involved in the HIV-1 integration process.
